IMCLONE - ein Stern beginnt zu funkeln - 500 Beiträge pro Seite

[catmat]

Nun ist es endgültig so weit:
Imclone hat in den letzten Tagen ganz unauffällig den Widerstand bei 100€ eindeutig und endgütig durchbrochen!
Wahrscheinlich gibt es in den nächsten Tagen die letzten billigen Einstiegschancen. Außerdem sollen Gute News anstehen. Ich habe mich schon angeschnallt und Warte ungeduldig auf die Zündung.

[IWA Japan]

@alle: obifes Beispiel zeigts doch mal wieder: gerade im BT Sektor gibt es genug unfundierte Meinungen:
1. €
2. Der Wiederstand liegt bei 105$
3. Pusher Argument: werden bald News kommen....
4. billig? sicherlich hat IMCL infolge seines potnetiellen Blockbuster Präparats noch mittel bis langsfristig ein großes Pot. , aber die Tatsache,dass der Wert in der letzten Zeit seit Ende Mai net so richtig lief ist für mich keein Überraschung, da die relative Bewertung überzogen war.

Es sollte immer auch der zeitöliche Faktor berücksichtigt werden


1. nach Abschluss von Phase III vergehen 6 Monate bis zur Zulassuzng und
2. weitere 6 ( i.d.Regel) bis zur Martkeinführung
3. zudem dauert es noch einge JAhre bis das volle Umsatzpotential entfalten ist...

[IWA Japan]

[Kauf]

Du sagst es, es gibt so viele unfundierte Meinungen, leider zählst du selbst dazu. Imclone will für C225 die Zulassung schon nach Phase 2 beantragen. Sicher wird es noch rund 9 Monate dauern bis es richtig auf dem Markt ist, aber die Börse bewertet nun mal die Zukunft! Im Vergleich zu anderen Biotechwerten sehe ich Imclone noch als günstig an und wenn die 100-105$ Zone übersprungen wird, dann sollte es richtig abgehen. Allerdings besteht immer noch die Gefahr, dass die Shorties weiter drücken und wir an der 100 scheitern. Aber bislang hält sie sich noch sehr gut!

Gruss

kauf

[IWA Japan]

[IWA Japan]

[IWA Japan]

so viel zum Thema fundiert

ab sofort werden dann wohl alle Präparate bereits nach sre II zugelassen, die III. Phase frisst dann der Affe ...


wenn du hier mit billig/teuer argumentierst, dann bring bitte Zahlen ....

zudem hat IMCL eine schlechte INfopolitik auf ihrer Homepage

habe bereits im Juni in einem Vergleich von KRebswerten prognostiziert, dass IMCL nicht so toll laufen wird wie etwa eine IDPH

Apropo Zukunft: bei IMCL scheint mir eben zu viel vorweggenommen,
auch wenn Charttechnisch brei einem Ausbruch Anschlusskäufe wohl stattfinden würden...

fundamental gesehen gibt es jedenfalls Werte mit einem besseren CHanche/Risiko Verhältnis

[IWA Japan]

wie gesagt: der Name sagt mal wieder alles...

@Manuel Kauf: gehe eher davon aus, dass du von einignen Analysten eher dich zu IMCL hast belehren lassen anstatt dich selbst mit IMCL zu beschäftigen.
Komischerweise haftet IMCL immer diese Prädikat aussichtsreich an, ohne das groß begründet wird,

aber dennoch, IMCL hat einen potentiellen Blockbuster in der Pipeline, llangfristig bei Ulassung weiterhin zimelich aussixhtsreich, aber an deiner ARgumentation und Vorgehensweise hier solltest du noch arbeiten


:rolleyeS:IWA

[IWA Japan]

Phase 1 = This is the initial test in humans for safety. This phase is to rule out inherently dangerous drugs that were not caught in the animal tests. Since we are different species this is absolutely necessary. Of course, some medications were ruled out in the animal phase which might have worked very well in humans. Common aspirin fits this picture. Aspirin causes abortions of mice and rat fetuses. Under todays rules aspirin could never reach the human testing stage.

Phase 2 = This is the efficacy trial. To make sure it does what the drug company claims. This and Phase 1 are usually small numbers of people.

Phase 3 = This is the large test and currently obesity control medicines are required to turn in 2 years of data. All other medications are required to turn in a one year study.

What is the best way to use the medication? This is the last Phase before FDA marketing approval. After this phase the studies conducted by the companies and others are given to a subcommittee of experts to review. If the subcommittee reviews and approves the medication it is passed to the FDA for final approval. Usually the full FDA committee follows the panel of experts advice.

Marketing = After final approval by the FDA the medication is manufactured and distributed to pharmacies and physicians. It is then available for you to use. One pharmacist said the process takes about 6 weeks after final approval. Another source said it can take up to two years.

Phase 4 = Any after-market studies recommended by the FDA or performed by the companies. This is where we go from having a few thousand people take the medicine to having millions of people taking it. This is where any rare side-effects may show up.

Phase 5 = Ongoing monitoring of clinical reports.

[IWA Japan]

APPROVAL PROCESS (For drugs in the US) according to law and FDA regulations involves 6 steps:

Preclinical--laboratory and animal studies
Company files for Investigational New Drug (IND) status with the FDA
Clinical trials begin:
1. Phase I: testing for safety

2. Phase II: testing for efficacy

3. Phase III: extensive clinical trials

4. Company files New Drug Application (NDA) with FDA for permission to market the drug

5. FDA review of application

6. FDA approval/rejection of application. Even after the NDA is approved, the company is required to periodically submit reports to the FDA, including adverse reactions data, production and quality control information and sometimes extended monitoring. See NDA, PHASE I, PHASE II, and PHASE III. (See Page 35 & 36).

Note: Women of "child-bearing potential" (anyone who is not surgically sterilized or post-menopausal) are kept out of Phase I, Phase II and even Phase III trials to protect drug companies from "potential legal liability" for a "potential fetus."

[IWA Japan]

keine Angst, noch mehr Quellen

Subpart B -- Investigational New Drug Applications (IND)

§ 312.20 Requirement for an IND.

(a) A sponsor shall submit an IND to FDA if the sponsor intends to conduct a clinical investigation with an investigational new drug that is subject to § 312.2(a).

(b) A sponsor shall not begin a clinical investigation subject to § 312.2(a) until the investigation is subject to an IND which is in effect in accordance with § 312.40.

(c) A sponsor shall submit a separate IND for any clinical investigation involving an exception from informed consent under
§ 50.24 of this chapter. Such a clinical investigation is not permitted to proceed without the prior written authorization from FDA. FDA shall provide a written determination 30 days after FDA receives the IND or earlier.

HISTORY:
[52 FR 8831, Mar. 19, 1987; 61 FR 51498, 51529, Oct. 2, 1996; 62 FR 32479, June 16, 1997]


§ 312.21 Phases of an investigation.

An IND may be submitted for one or more phases of an investigation. The clinical investigation of a previously untested drug is generally divided into three phases. Although in general the phases are conducted sequentially, they may overlap. These three phases of an investigation are a follows:

(a) Phase 1.

(1) Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug`s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80.
(2) Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.

(b) Phase 2. Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.
(c) Phase 3. Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects.

HISTORY:
[52 FR 8831, March 19, 1987]


§ 312.22 General principles of the IND submission.

(a) FDA`s primary objectives in reviewing an IND are, in all phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the drug`s effectiveness and safety. Therefore, although FDA`s review of Phase 1 submissions will focus on assessing the safety of Phase 1 investigations, FDA`s review of Phases 2 and 3 submissions will also include an assessment of the scientific quality of the clinical investigations and the likelihood that the investigations will yield data capable of meeting statutory standards for marketing approval.

(b) The amount of information on a particular drug that must be submitted in an IND to assure the accomplishment of the objectives described in paragraph (a) of this section depends upon such factors as the novelty of the drug, the extent to which it has been studied previously, the known or suspected risks, and the developmental phase of the drug.

(c) The central focus of the initial IND submission should be on the general investigational plan and the protocols for specific human studies. Subsequent amendments to the IND that contain new or revised protocols should build logically on previous submissions and should be supported by additional information, including the results of animal toxicology studies or other human studies as appropriate. Annual reports to the IND should serve as the focus for reporting the status of studies being conducted under the IND and should update the general investigational plan for the coming year.

(d) The IND format set forth in § 312.23 should be followed routinely by sponsors in the interest of fostering an efficient review of applications. Sponsors are expected to exercise considerable discretion, however, regarding the content of information submitted in each section, depending upon the kind of drug being studied and the nature of the available information. Section 312.23 outlines the information needed for a commercially sponsored IND for a new molecular entity. A sponsor-investigator who uses, as a research tool, an investigational new drug that is already subject to a manufacturer`s IND or marketing application should follow the same general format, but ordinarily may, if authorized by the manufacturer, refer to the manufacturer`s IND or marketing application in providing the technical information supporting the proposed clinical investigation. A sponsor-investigator who uses an investigational drug not subject to a manufacturer`s IND or marketing application is ordinarily required to submit all technical information supporting the IND, unless such information may be referenced from the scientific literature.

[IWA Japan]

Figure 5.1 Stages of Clinical Testing

5.5


--------------------------------------------------------------------------------

Drug development is a long and financially risky process. For every drug that ultimately reaches clinical testing through an IND, thousands of drugs are synthesized and tested in the laboratory. And only about one in five drugs initially tested in humans successfully secures FDA approval for marketing through a new drug application. 19
The manufacturer submits an NDA to FDA to gain approval for marketing clinical testing is complete. An NDA is a massive document, the largest portion of which contains the clinical data from Phase I-III testing. The other technical sections of an NDA include chemistry, manufacturing, and controls; nonclinical pharmacology and toxicology; and human pharmacokinetics and bioavailability. 23 In the case of a new cannabinoid, an abuse liability assessment would also probably be part of an NDA submission. In 1996, the median time for FDA review of an NDA, from submission to approval, was 15.1 months, a review period considerably shorter than that in 1990, when the figure was 24.3 months. 22 The shortening of approval time is an outgrowth of the Prescription Drug User Fee Act of 1992, which authorized FDA to hire additional review staff with so-called user fees paid by industry, and imposed clear deadlines for FDA action on an NDA. With respect to the cost of a single drug`s development, a number of recent studies have provided a range of estimates of about $200-300 million, depending on the method and year of calculation. 33, 44
With FDA approval of an NDA, the manufacturer is permitted to market the drug for the approved indication. At that point, although any physician is at liberty to prescribe the approved drug for another indication (an "off-label use"), the manufacturer cannot promote it for that indication unless the new indication is granted separate marketing approval by the FDA. a To obtain such approval, the manufacturer is required to compile another application to the FDA for what is known variously as an "efficacy supplement," a "supplemental application", or a "supplemental new drug application". Those terms connote that the application is supplemental to the NDA. In general, collecting new data for FDA approval of an efficacy supplement is not as intensive a process as that for an NDA; it generally requires the firm to conduct two additional Phase III studies, although under some circumstances only one additional study of the drug`s efficacy is needed.24 The preclinical studies, for example, ordinarily need not be replicated. The average cost to the manufacturer for obtaining approval for the new indication is typically about $10-40 million.33 The review time for FDA approval of the new indication can be considerable; a recent study of supplemental indications approved by FDA inl989-1994 found the approval time to exceed that for the original NDA,18 a reflection, in part, of the lower priority FDA accords to the review of efficacy supplements as opposed to new drugs.
--------------------------------------------------------------------------------

a FDA policies for off-label use are being transformed as a result of the Food and Drug Administration Modernization Act of 1997, which, FDA recently promulgated new rules to give manufacturers greater flexibility to disseminate information about off-label uses (FDA, 1998b). As of this writing, however, court decisions have left the status of the new rules somewhat unclear.

[IWA Japan]

Figure 3 Terminology:

IND - Investigational New Drug Application. FDA regulatory document allowing clinical trials to proceed on an investigational medicine or investigational use of an approved marketing medicine.

NDA – New Drug Application. An application to the FDA for approval of a new medicine in the United States.

Phase I - Initial safety trials on a new medicine, usually conducted in normal male volunteers. An attempt is made to establish the dose rage tolerated by volunteers for single and multiple doses. Phase I trials are sometimes conducted in severely ill patients or in less ill patients when pharmacokinetic issues are addressed. Pharmacokinetic trials are usually considered phase I trials regardless of when they are conducted during a medicine`s development.

Phase IIa - Pilot clinical trials to evaluate efficacy (and safety) in selected populations of patients with the disease or condition to be treated, diagnosed, or prevented. Objectives may focus on dose-response, type of patient, frequency of dosing, or numerous other characteristics os safety and efficacy.

Phase IIb - Well-controlled trials to evaluate efficacy (and safety) in patients with the disease or condition to be treated, diagnosed, or prevented. These clinical trials usually represent the most rigorous demonstration of a medicine`s efficacy. Sometimes referred to as pivotal trials.

Phase IIIa - Trials conducted after efficacy of the medicine is demonstrated, but prior to regulatory submission of New Drug Application (NDA) or other dossier. These clinical trials are conducted in patient populations for which the medicine is eventually intended. Phase IIIa clinical trials generate additional data on both safety and efficacy in relatively large numbers of patients in both controlled and uncontrolled trials. Clinical trials are also conducted in special groups of patients, or under special conditions.

Phase IIIb - Clinical trials conducted after regulatory submission of an NDA or other dossier, but prior to the medicine`s approval and launch. These trials may supplement earlier trials, complete earlier trials, or may be directed toward new types of trials or Phase IV evaluations. This is the period between submission and approval of a regulatory dossier for marketing authorization.

Phase IV - Studies or trials conducted after a medicine is marketed to provide additional details about the medicine`s efficacy or safety profile. Different formulation, dosages, duration of treatment, medicine interactions, and other medicine comparisons may be evaluated. New age groups, races, and other types of patients can be studied. Detection and definition of previously unknown or inadequately quantified adverse reactions and related risk factors are an important aspect of many Phase IV studies.

[IWA Japan]

was hier noch untergegangen ist, ist die Tatsache, dass IMCL C225 in mehreren Phase II und III Studien testet:


Clinical Trials - IMC-C225


Clinical trials of IMC-C225 currently enrolling patients are as follows:


Head and Neck Cancer

a dose-ranging phase Ib/IIa trial in newly diagnosed, stage II, III, or IV patients of three weekly infusions of IMC-C225 followed by surgical resection. The primary objectives of this study are to determine the plasma pharmacokinetics, tumor localization/receptor saturation, and safety of IMC-C225 at the doses studied. This multi-center study is open to patient enrollment.


a phase II trial in patients with locally advanced, newly diagnosed or recurrent disease who are treated with IMC-C225 in combination with Cisplatin® and concomitant boost radiation therapy. The primary objectives of this study are to determine the response rate and safety of this multi-modality therapy. This single-center study is open to patient enrollment.


a phase II trial for patients with recurrent or metastatic disease, who are treated with an induction chemotherapy regimen of platinum in combination with either Taxol® or 5-FU. Patients who fail to respond to two courses of the induction chemotherapy regimen will then receive IMC-C225 in combination with platinum only. The primary objectives of this study are to determine the response rate and safety of IMC-C225 in combination with Cisplatin® therapy. This multi-center study is open to patient enrollment.


a randomized, double blind, placebo-controlled phase III study of patients, either newly diagnosed with extensive incurable local-regional disease and distant metastases, or local-regional recurrence/persistence, or with distant metastases after initial treatment with surgery or radiation therapy. Patients are treated with standard monthly Cisplatin® in combination with either placebo or IMC-C225. The primary objectives of this study are to compare the time to disease progression and toxicity of Cisplatin®/IMC-C225 with Cisplatin®/placebo. This cooperative group study is open to patient enrollment.


a randomized phase III study in patients with locally advanced disease. Patients are treated with radiation therapy alone or radiation therapy plus 8 weeks of IMC-C225. Patients are stratified for four factors, including radiation schedule (once- or twice-daily or concomitant boost). The primary objectives are to examine differences in locoregional disease control maintained for one year and safety (acute and late radiation effects) between the two treatment groups. This multi-center, multi-national study is open to patient enrollment.

[IWA Japan]

[IWA Japan]

so, glaube die obigen 5 gleichlautenden Quellen reichen dan mal aus

[IWA Japan]

down

[Kauf]

Lieber IWA Japan, lachst du über deine eigene Dummheit?

Auch wenn ich nicht auf diesem Niveau diskutieren will, ich bin täglich im Yahooboard, und verfolge IMCL regelmässig. Natürlich werden Medikamente normalerweise erst nach P3 zugelassen, wenn sie aber lebenwichtig/rettend für die Patienten sind, dann ist auch eine schnellzulassung möglich. Imclone hatte am 11.8. ein Meeting mit der FDA, man hat sich die Daten angeschaut und die FDA hat Imclone grünes Licht gegeben die Zulassung für C225 aufgrund von P2 zu beantragen. Oder was meinst du warum die an einem Tag von 70 auf 85 steigen?

Das kann man übrigens auch in Pressemitteilungen und anderen Berichten nachlesen. Wenn du dich lächerlich machen willst, dann mach doch bitte weiter so. Du bist hier derjenige der sich aufspielen will, aber Ahnung hast du von IMCL null komma null!

MfG

Manuel Kauf

[IWA Japan]

würde ja gerne mal reinstellen wie lachhaft du aussiehst

aber bitteschön

[IWA Japan]

1. schau dir mal die Qualität der Postings hier in diesem THread an, dann wirst du leider sehr schnell feststellen, dass ich zu den wenigen gehöre, die hier konstruktive Beiträge liefern...

2. deine Homepage ist schlechter als miserabel...

[IWA Japan]

na gut, ich entschuldige mich.

Habe diese News bei IMCL verpasst bzw. es übersehen

Click Here!
Related Quotes

IMCL
94 3/4
-3 1/4

delayed 20 mins - disclaimer


Monday August 14, 2:51 pm Eastern Time
ImClone to seek U.S. OK of drug for colon cancer
NEW YORK, Aug 14 (Reuters) - The chief executive of ImClone Systems Inc (NasdaqNM:IMCL - news) said on Monday he expects the firm by the first quarter of 2001 to seek U.S. marketing approval of its experimental drug C225 for patients with colorectal cancer who have failed on previous standard chemotherapy treatments.

Samuel Waksal, CEO of the New York-based firm, added in an interview that he expects ``toward the end of the first half of 2001`` to seek U.S. marketing approval of the drug for patients with head and neck cancer who have also failed earlier therapies.

Phase II clinical trials of C225 are now under way in patients with colorectal and head and neck cancer. Final data from the trials, when obtained, will be the basis for the separate marketing applications, Waksal said.

``If all goes well, C225 will be on the market in the fourth quarter of 2001`` for colorectal cancer, said Waksal, whose brother Harlan is chief operating officer of ImClone.

But for C225 to reach doctors by that optimistic timetable, the drug will have to receive a six-month fast-track review by the U.S. Food and Drug Administration. Usually the agency takes 12 months to decide whether to approve new medicines, but it acts more swiftly when drugs are novel or target especially difficult-to-treat diseases.



Dennoch gilt:
1. du gibst dich zimelich arrogant. sicherlich habe ich auch etwads aufgetragen, aber dann im Anschluss dies in Sachlicher Diskussion münden lassen..., aber egal

2. Dennoch besteht hier keinerlei Anlass, diese Konfrotation , die auf einem Irrtum beruhte, weiterzuführen.

Im Gegentiel bin ich froh, dich eventuell als konstruktiven Poster hier in diesem BOard begrüssen zu dürfen

[Kauf]

Hallo!

Falls ich arrogant gewirkt habe bitte ich dies auch zu entschuldigen. Ich war eigentlich auch an einer sachlichen Diskussion interessiert. Ich finde es eigentlich schade, dass du gleich auf die persönliche Ebene gehst. Schau dir mal diesen Thread an, er hat 21 Beiträge, davon sind ganze 18 von dir. Zuerst hast du mal angefangen mit persönlichen Beleidigungen, erst dann hast du mal nachgeschaut, ob es vielleicht doch stimmen könnte.

Wie du siehst poste ich sehr selten, das wird auch in Zukunft so bleiben. Auf sowas hier kann ich gut verzichten!

Falls mich jemand sehen will kann er gerne auf www.manuel-kauf.de oder wenn er wirklich an einer sachlichen Diskussion interessiert auf www.aktie2010.de Dort reden wir zwar hauptsächlich über Senetek, aber jeder ist herzlichst willkommen. Bei diesem Thema spalten sich auch die Meinungen sehr, aber bei mir im Board bleiben alle sachlich.

Ich hoffe, das war jetzt nicht wieder zu arrogant

Kauf

PS: Nicht alles gleich so ernst nehmen, okay?!

[IWA Japan]

1, habe mich entschuldigt, was du akzeptiertest , ist also OK
2, bin in der Tat etwas impulsiv

3. hier zu postern lohnt sich net, da viele da sind, die keien KEnntnise haben und zudem auch über einen mangelnde Diskussionsfähigkeit verfügen....


4. ich gehöre nicht dazu, bin immer an intersanten Diskusionen interssiert.

Sicherlich habei ch etwas iumpulsiv reagiert, aber das hat sich ja jatzt geklärt

Gruß

IWA

[Nummer2]

Hi, Ihr beiden Streithähne!

Erstmal Gratulation zur Versöhnung !

Zum Thema: Ich war auch in IMCL investiert, habe viel Lehrgeld bezahlt. Ich bin nach Veröffentlichung der C-225-Studien auf Grund von vorbörslichem Kursanstieg rein, noch am selben Tag fing der Kursrutsch an. Sell-on-good-news, miserable Testergebnisse der Mitbewerber, mit denen Imclone in einen Topf geworfen wurde etc. etc. Jedenfalls rechnete ich wochenlang mit einem Anstieg des Kurses, der trotz guter News leider nicht erfolgen wollte. Deshalb bin ich beim jetzigen Anstieg erstmal raus, leider ein bißchen zu früh.
Aus Imclone werde ich nicht schlau. Der Kurs macht immer etwas anderes als man erwartet. Auch dieser Widerstand bei 105 $ scheint stabil zu sein. Ich vermute, dass es jetzt erstmal wieder weit runtergeht. Jedenfalls werde ich erst bei 70 $ wieder einsteigen. Momentan gibt es bessere Biotech-Werte.

Bye, Nummer2

[METOX]

Hi IWA,

ich schätze Deine Beiträge zwar sehr, aber vor kurzem gab es ein Treffen zwischen dem Imclone CEO und der FDA: Man verhandelte bei dieser Zusammenkunft darüber, ob Imclone mit seinem Mittel C225 die Phase III überspringen dürfe...

According to Merrill Lynch analyst Eric Hecht, based on the interim data the FDA now believes that ImClone`s Phase II studies may qualify for accelerated approval for both indications. That outcome, writes Hecht, ``eliminates concern that the FDA might request a Phase III trial before considering approval.``

The FDA`s thumbs up cheered investors, since it means that ImClone can bypass the Phase III trial period and that the company is on track to file its application for colorectal cancer during the first quarter, and for head and neck cancer in the second quarter of 2001. Assuming a six-month review, C225 could be on the U.S. market as soon as the fourth quarter of 2001.

Quelle: http://biz.yahoo.com/ii/000823/industry_000823.html


MfG Metox

PS: Deine Arroganz hättest Du Dir sparen können. Du kannst sicher sein, daß in diesem Board auch andere viel Zeit und Fleiß in Research investieren...

[IWA Japan]

dann sind ja allrjetzt zufrieden....

[IWA Japan]

2. Wer ist bitte Mr. Roboto

A: keiner

[MoneyMoneyMoney]

ImClone geht ab !!!!
Schon 124 Euro in Frankfurt und die 105 $ sind auch geknackt !

MMM

[Magic Mitch]

@ MMM: Ab 15:00 gings´s steil nach oben... weißt Du, warum? Gab´s irgendwelche News, die diesen Anstieg rechtfertigen?

Magic Mitch

[faxefaxe]

naja, sie haben ja lange genug anlauf genommen, um über die 100/102 dollar zu kommen. das gibt schwung. gruß, faxe